Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Cabaletta Bio Inc (NASDAQ: CABA) closed at $2.18 in the last session, up 5.83% from day before closing price of $2.06. In other words, the price has increased by $5.83 from its previous closing price. On the day, 2.05 million shares were traded.
Ratios:
We take a closer look at CABA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.96 and its Current Ratio is at 3.96. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Evercore ISI on December 20, 2024, Downgraded its rating to In-line and sets its target price to $6 from $15 previously.
On December 19, 2024, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight and also lowered its target price recommendation from $12 to $6.
On October 10, 2024, UBS started tracking the stock assigning a Buy rating and target price of $10.UBS initiated its Buy rating on October 10, 2024, with a $10 target price.
Stock Price History:
Over the past 52 weeks, CABA has reached a high of $13.50, while it has fallen to a 52-week low of $0.99. The 50-Day Moving Average of the stock is 52.17%, while the 200-Day Moving Average is calculated to be -23.19%.
Shares Statistics:
A total of 50.74M shares are outstanding, with a floating share count of 46.16M. Insiders hold about 9.03% of the company’s shares, while institutions hold 67.14% stake in the company.
Earnings Estimates
Cabaletta Bio Inc (CABA) is presently subject to a detailed evaluation by 6.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.67, with high estimates of -$0.35 and low estimates of -$0.83.
Analysts are recommending an EPS of between -$1.38 and -$3.2 for the fiscal current year, implying an average EPS of -$2.35. EPS for the following year is -$2.11, with 6.0 analysts recommending between -$0.95 and -$3.11.
